The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has published an updated register of licensed manufacturing sites for both human and veterinary medicines, focusing specifically on manufacturer specials authorisations. This regulatory database serves as a critical tool for healthcare professionals and pharmaceutical companies to verify licensed production facilities across the UK.
Key takeaways
- MHRA maintains comprehensive register of licensed manufacturing sites for medicines production
- Database covers both human manufacturer specials (MS) and veterinary manufacturer specials authorisation (MANSA) facilities
- Register provides transparency in pharmaceutical manufacturing oversight and regulatory compliance
MHRA Manufacturing Oversight Framework
Regulatory categories for licensed pharmaceutical production sites
Source: MHRA, 2024 | Georgian Medical Journal News
Regulatory Framework for Manufacturing Oversight
The MHRA’s manufacturing register represents a cornerstone of pharmaceutical quality assurance in the UK healthcare system. This database enables healthcare professionals, pharmacists, and regulatory bodies to verify the licensing status of facilities producing specialist medicines.
Manufacturer specials, also known as unlicensed medicines, are produced to meet specific patient needs when licensed alternatives are unavailable or unsuitable. The regulatory oversight of these facilities ensures adherence to Good Manufacturing Practice (GMP) standards.
Implications for Healthcare Practice
The register’s dual coverage of human and veterinary manufacturing sites reflects the interconnected nature of pharmaceutical production and One Health approaches to medicine regulation. Healthcare professionals can use this database to verify the credentials of suppliers and ensure patient safety through supply chain transparency.
Pharmaceutical companies seeking to establish or maintain manufacturing operations must demonstrate compliance with MHRA standards to achieve and retain listing in this official register. This creates accountability within the pharmaceutical supply chain.
Access and Transparency in Medicine Manufacturing
The public availability of this manufacturing register demonstrates the MHRA’s commitment to transparency in pharmaceutical regulation. This approach aligns with broader trends toward regulatory transparency across European medicines agencies.
Healthcare systems benefit from this transparency through improved ability to assess supply chain resilience and manufacturing capacity. The register serves as a valuable resource for understanding the geographic distribution of licensed manufacturing capabilities across the UK. This information becomes particularly relevant during supply chain disruptions or public health emergencies.
The MHRA register provides comprehensive oversight of licensed manufacturing sites for both human manufacturer specials (MS) and veterinary manufacturer specials authorisation (MANSA) facilities
— UK Medicines and Healthcare products Regulatory Agency (MHRA Register, 2024)
What this means
Frequently asked questions
What are manufacturer specials in pharmaceutical regulation?
Manufacturer specials are unlicensed medicines produced to meet specific patient needs when licensed alternatives are unavailable or unsuitable. They must be manufactured under MHRA oversight in licensed facilities.
How does the MHRA ensure quality in unlicensed medicine production?
The MHRA requires all manufacturing sites to demonstrate compliance with Good Manufacturing Practice standards and maintains ongoing oversight through inspection and licensing requirements.
Why does the register cover both human and veterinary medicines?
Many pharmaceutical manufacturing facilities produce both human and veterinary medicines, and regulatory oversight follows One Health principles recognizing the interconnected nature of medicine safety across species.
The MHRA’s comprehensive approach to manufacturing oversight through this register reflects the agency’s commitment to maintaining high standards across all pharmaceutical production categories. As healthcare systems continue to rely on specialist medicines to meet diverse patient needs, transparent regulatory frameworks like this register become increasingly important for ensuring both quality and supply chain resilience in pharmaceutical manufacturing.
Source: Human and veterinary medicines: register of licensed manufacturing sites
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
